Less than a week after Cell Therapeutics Inc. (CTI) snagged a handsome deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor pacritinib – adding another industry vote for the approach – Sanofi SA disclosed safety problems with its JAK inhibitor fedratinib and ended the Phase III effort, which sparked a new look at the class.